Medicare Rebates On Drug ‘Wastage’: New Products Get Limited Time Reprieve
Regulation from CMS may drive manufacturers to repackage Medicare Part B drugs sold in single-use containers to avoid waste that would be subject to new rebate.
You may also be interested in...
The upcoming implementation of a new ‘refund’ program for unused drugs included in single-use vials is a remarkable story of a policy idea moving from academic research into the real world. But the actual impact sure has shrunk along the way.
Manufacturers who sell single-use vials for products covered by Part B have about 16 months to consider pricing or packaging changes that may minimize exposure to a new refund for ‘wasted’ drug.
Amgen, Takeda and Merck push back against article’s conclusions on the waste generated by current vials for infused drugs.